The US government banned the use of Chinese AI startup DeepSeek's technology in federal agencies, citing security risks, while DeepSeek responded by open-sourcing its DeepInfer inference engine. Otter.ai secured $320 million in funding to advance its AI meeting assistant and expand internationally. Additionally, OpenAI acquired Orchestra Bio to enhance its AI capabilities in drug development and life sciences research. These developments highlight ongoing tensions in AI geopolitics alongside significant investments in enterprise AI and biotech applications.
Orchestra Bio
- trend score
- 1.60
- sources
- 4
- mentions
- 4
Flash OpenAI acquires Orchestra Bio to integrate AI-powered operations into its Rosalind life sciences tools, accelerating drug development and advancing treatments.
Daily mentions evolution
- Oct 20: OpenAI acquires Orchestra Bio to integrate AI-powered operations into its Rosalind life sciences tools, accelerating drug development and advancing treatments.